Optimizing ELQs for Treatment and Prevention of Malaria

优化 ELQ 以治疗和预防疟疾

• 批准号: 8776262
• 负责人: Michael Kevin RISCOE
• 金额: $ 61.34万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-12-01 至 2017-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8776262
• 关键词: Antimalarials; Apicomplexa; Atovaquone resistance; Birds; Bite; Blood; Blood Circulation; Cessation of life; Chemicals; Child; Chloroquine; Collaborations; Culicidae; Development; Disease; Doctor of Philosophy; Dose; Drug Targeting; Drug resistance; Drug usage; Employee Strikes; Exhibits; Finches; Floods; Goals; Health; Human; In Vitro; Infection; Inhibitory Concentration 50; Laboratories; Lead; Left; Life Cycle Stages; Liver; Malaria; Malaria prevention; Mammals; Medicine; Meleagris gallopavo; Metabolic; Modeling; Multi-Drug Resistance; Mus; Oral; Parasites; Performance; Pharmaceutical Chemistry; Pharmaceutical Preparations; Plasmodium; Plasmodium falciparum; Population; Pregnant Women; Prophylactic treatment; Quinolones; Reporting; Resources; Role; Route; Rupture; Serinus; Sporozoites; Staging; Symptoms; Testing; Time; Vivax Malaria; Vulnerable Populations; Work; analog; design; disease transmission; in vivo; interest; killings; male; member; mutant; prevent; programs; prophylactic; quinolone resistance; resistance frequency; resistance mechanism; transmission process; vector mosquito

DESCRIPTION (provided by applicant): Drugs targeting the liver stage offer many advantages over drugs that merely target the blood stage. First, drugs active against the liver stage represent true causally prophylactic agents that can prevent all disease symptoms, including death, associated with malaria. Secondly, it has been established that while wild-caught mosquitoes may harbor thousands of sporozoites, only ~10 sporozoites are transferred in a single bite to the human host. Over the next 2-3 weeks the sporozoite reproduces in the liver to produce 10,000-30,000 descendants before the schizont ruptures and parasites flood into the bloodstream where the absolute parasite burden may increase to ten thousand billion (1013) circulating plasmodia. Clearly it is advantageous to strike at the liver stage where parasite numbers are low, to diminish the likelihood of selecting for a drug resistant mutant and before the infection has a chance to weaken the defenses of the human host. Our primary goal in this project is to develop a non-quinoline drug that is active against P. falciparum and P. vivax malaria, targeting the parasite in the liver and blood stages, and including the gametocytes. Studies (by us and others) have shown that the Endochin-like Quinolone (ELQ) chemotype targets all 3 of these life cycle stages. The ultimate objective of our proposed work is the development of an inexpensive ELQ that can be co-formulated with other antimalarials in a synergistic combination to prevent and treat malaria, and can serve to assist in eradication of the disease worldwide. Our study of endochin, a drug discovered by Andersag in the 1940's) showed that the primary cause of its poor performance in mammals is due to its metabolic instability. More recently we have developed ELQ analogs with subnanomolar IC50 values against multidrug resistant and atovaquone resistant parasites, curative efficacy in murine models of malaria at oral doses of 1mg/kg/day, as well as prophylaxis against sporozoite induced infections at 3mg/kg/day (the lowest dose studied). In this application we seek to continue to explore the chemical space around the quinolone chemotype in order to develop this antimalarial class to the fullest of its potential. As described in the narrative of this proposal e have already discovered an ELQ derivative that is curative in malaria infected mice at 0.1mg/kg/day (4 days) via multiple routes of administration. The Specific Aims of this application are: 1. Lead optimization of ELQ antimalarials, 2. Characterization of the ELQ mechanism(s) of action, and 3. Characterization of ELQ resistance mechanisms and assessment of ELQ resistance frequency in populations of P. falciparum parasites. Development of an ELQ for human use could dramatically change the way in which malaria is managed worldwide. Because ELQs are active against multiple developmental stages of infection they could be used to prevent and treat malaria and also could have a major role in eradicating the disease.

描述（由申请人提供）：靶向肝脏阶段的药物比仅靶向血液阶段的药物具有许多优势。首先，对肝脏阶段有活性的药物是真正的因果预防剂，可以预防与疟疾有关的所有疾病症状，包括死亡。其次，已经确定，虽然野外捕获的蚊子可能携带数千个子孢子，但在单次叮咬中只有约10个子孢子转移到人类宿主。在接下来的2-3周内，子孢子在肝脏中繁殖以产生10，000 - 30，000个后代，然后鞭毛破裂，寄生虫涌入血液，其中绝对寄生虫负荷可能增加到一万亿（1013）个循环疟原虫。显然，在寄生虫数量较少的肝脏阶段进行攻击是有利的，以减少选择耐药突变体的可能性，并且在感染有机会削弱人类宿主的防御之前。我们在该项目中的主要目标是开发一种非喹啉药物，该药物对恶性疟原虫和间日疟原虫疟疾有效，靶向肝脏和血液阶段的寄生虫，包括配子体。我们和其他人的研究表明，Endochin样喹诺酮（ELQ）化学型靶向所有3个生命周期阶段。我们所提出的工作的最终目标是开发一种廉价的ELQ，它可以与其他抗疟药协同组合共同配制，以预防和治疗疟疾，并有助于在世界范围内根除这种疾病。 我们对安德萨格在20世纪40年代发现的药物endochin的研究表明，其在哺乳动物中表现不佳的主要原因是由于其代谢不稳定。最近，我们开发了ELQ类似物，其对多药耐药和阿托伐醌耐药寄生虫的IC 50值低于纳摩尔，口服剂量为1 mg/kg/天时在疟疾小鼠模型中具有疗效，以及预防3 mg/kg/天（研究的最低剂量）的子孢子诱导的感染。在本申请中，我们寻求继续探索喹诺酮化学型周围的化学空间，以最大限度地开发这种抗疟药物。如本提案叙述中所述，我们已经发现了一种ELQ衍生物，其通过多种给药途径以0.1 mg/kg/天（4天）的剂量对疟疾感染小鼠具有治疗作用。本申请的具体目的是：1.领导优化ELQ抗疟药，2。ELQ作用机制的表征，以及3.恶性疟原虫群体中ELQ抗性机制的表征和ELQ抗性频率的评估。 开发人类使用的ELQ可能会极大地改变全球疟疾管理的方式。由于ELQ对感染的多个发展阶段都有活性，因此它们可用于预防和治疗疟疾，并在根除疟疾方面发挥重要作用。